A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

BACKGROUND/OBJECTIVES: This article compares the effectiveness of baricitinib (BARI) 4 mg (oral, Janus kinase [JAK] 1/2 inhibitor) versus other targeted synthetic/biologic disease-modifying antirheumatic drugs, in combination with methotrexate (MTX), in moderate-to-severe rheumatoid arthritis patien...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Health Econ Outcomes Res
Hlavní autoři: Fakhouri, Walid, Wang, Xiaofei, de La Torre, Inmaculada, Nicolay, Claudia
Médium: Artigo
Jazyk:Inglês
Vydáno: Columbia Data Analytics, LLC 2020
Témata:
Autoimmune Diseases
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7299462/
https://ncbi.nlm.nih.gov/pubmed/32685594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36469/jheor.2020.12273
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky